CYP3A5 rs776746: Understanding Your Pharmacogenetic Profile

What each genotype means

What is the rs776746 Variant?

The rs776746 variant, often referred to in clinical literature as the CYP3A5*3 allele, is a single-nucleotide polymorphism (SNP) located within the CYP3A5 gene on chromosome 7. Specifically, this variant involves a change in the DNA sequence that creates a cryptic splice site. This alteration leads to the incorrect processing of the gene's messenger RNA, resulting in the inclusion of an extra segment known as exon 3B. Consequently, the cellular machinery produces a nonfunctional protein that is often degraded through a process called nonsense-mediated mRNA decay. Because this variant prevents the production of a working enzyme, individuals who carry two copies of this variant are considered 'non-expressers' of the CYP3A5 protein. This genetic change is a classic example of how a single DNA letter difference can fundamentally alter the functional output of a gene, thereby influencing how the body interacts with certain chemical compounds and medications.

The Role of the CYP3A5 Gene

The CYP3A5 gene provides instructions for making an enzyme that belongs to the cytochrome P450 family. These enzymes are primarily located in the liver and the lining of the small intestine, where they play a critical role in the metabolism of a wide variety of substances, including endogenous compounds and exogenous drugs. CYP3A5 is particularly important for the breakdown of tacrolimus, an immunosuppressant medication frequently prescribed to prevent organ rejection in transplant recipients. When the CYP3A5 enzyme is present and active, it helps clear tacrolimus from the bloodstream. However, when the enzyme is absent—as is the case in individuals with the rs776746 variant—the body's ability to metabolize this drug is significantly reduced. This can lead to higher concentrations of the medication in the blood, which necessitates careful monitoring and potential dose adjustments by healthcare providers to ensure the drug remains within a safe and effective therapeutic range.

Research and Clinical Associations

Research into rs776746 is robust, particularly within the field of pharmacogenomics. Numerous studies have established a strong association between this variant and tacrolimus clearance rates. Because the variant is a loss-of-function mutation, patients who are homozygous for the variant (carrying two copies) typically require lower doses of tacrolimus compared to those who carry at least one functional copy of the gene. The Clinical Pharmacogenetics Implementation Consortium (CPIC) has published guidelines that incorporate this genetic information to help clinicians optimize initial dosing strategies. While the evidence linking this SNP to tacrolimus metabolism is strong, it is important to note that other factors, such as age, liver function, and interactions with other medications, also influence drug levels. Therefore, genetic testing is used as a tool to support, rather than replace, clinical judgment and therapeutic drug monitoring. Always consult with your transplant team or pharmacist regarding any medication dosing questions.

Population Frequency

The frequency of the rs776746 variant varies significantly across different global populations. In European populations, the variant is highly common, with a minor allele frequency often exceeding 0.90. In contrast, the variant is less common in African populations, where the frequency typically ranges between 0.15 and 0.30. East Asian populations show intermediate frequencies, generally falling between 0.65 and 0.75. These differences mean that the proportion of 'non-expressers'—individuals who lack functional CYP3A5 enzyme activity—differs widely depending on ancestral background. Understanding these population-specific frequencies is essential for clinicians when interpreting the potential impact of this variant on a patient's drug metabolism, as it highlights that genetic predispositions are not distributed uniformly across the human population.

What You Can Do With This Information

If you have received results regarding your rs776746 genotype, the most important step is to discuss these findings with your healthcare provider, especially if you are currently taking or are expected to take tacrolimus. This information is intended for educational purposes and should not be used to make independent decisions about your medication. Your doctor or pharmacist can interpret your genotype in the context of your overall health, other medications you may be taking, and your specific clinical needs. They are the only ones qualified to determine if a dose adjustment is necessary based on your genetic profile. Do not stop or change the dosage of any prescribed medication without professional medical guidance. Genetic information is a powerful tool for personalized medicine, but it is most effective when integrated into a comprehensive care plan managed by your clinical team.

Frequently asked questions

Sources & further reading

Related variants in CYP3A5